Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
Status:
Completed
Trial end date:
2019-04-18
Target enrollment:
Participant gender:
Summary
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2
dose (RP2D) of oral BAY1217389 given in combination with intravenous (IV) paclitaxel using an
intermittent dosing schedule (2 days on / 5 days off) in subjects with advanced malignancies.